Vantage Financial Partners (Wisconsin)’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-8,050
Closed -$449K 65
2022
Q2
$449K Buy
8,050
+50
+0.6% +$2.77K 0.26% 26
2022
Q1
$444K Buy
8,000
+4,000
+100% +$205K 0.23% 34
2021
Q4
$224K Buy
+4,000
New +$217K 0.09% 53

Other funds holding NVO

Vantage Financial Partners (Wisconsin)'s NVO Position: Q3 2022 in Review

Vantage Financial Partners (Wisconsin) sold out of Novo Nordisk (NVO) in Q3 2022, closing a stake of 8,050 shares — an estimated $449K sold.

Vantage Financial Partners (Wisconsin) first reported a position in NVO in Q4 2021 and held it in 3 quarters. The position peaked at $449K in Q2 2022. 907 funds tracked by Wall St. Rank hold NVO as of Q3 2022.

  • Vantage Financial Partners (Wisconsin) reported no remaining Novo Nordisk position as of Q3 2022 after selling out during the quarter.
  • Vantage Financial Partners (Wisconsin) sold 8,050 Novo Nordisk shares in Q3 2022, an estimated $449K.
  • Vantage Financial Partners (Wisconsin) first reported a position in Novo Nordisk in Q4 2021 and held it in 3 quarters.
  • Vantage Financial Partners (Wisconsin)'s Novo Nordisk position peaked at $449K in Q2 2022.
  • 907 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2022.

Based on Vantage Financial Partners (Wisconsin)'s 13F filing for Q3 2022, filed 31 Oct 2022.